# US 10,869,854 B2 · Method for treating skin cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,869,854 B2 - Document ID: US10869854B2 - Status: Granted - Kind: B2 - Application number: 16/681,379 - Filed: 2019-11-12 - Published: 2020-06-04 - Granted: 2020-12-22 - Earliest claimed: 2012-07-26 - Assignees: The William M. Yarbrough Foundation - Applicants: Michael E. Silver - Inventors: Michael E. Silver - Web page: https://patentgrep.com/patent/US10869854B2 ## CPC - A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 31/16: Amides, e.g. hydroxamic acids - A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) - A61P 17/00: Drugs for dermatological disorders - A61P 35/00: Antineoplastic agents - C07C 331/20: of a saturated carbon skeleton - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS ## Abstract A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. ## Claims ### Claim 1 A method for treating skin cancer, comprising the step(s) of: administering a surfactant or a pharmaceutically acceptable salt thereof to a patient having skin cancer, wherein the protonated form of the surfactant is represented by the following chemical structure: wherein R1 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and cyano group containing 1 to approximately 25 carbon atom(s); wherein R2 is NCS; and wherein R3-R5 are each independently selected from the group consisting of H, OH, and an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and/or cyano group containing 1 to approximately 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and/or cyano group containing approximately 8 to approximately 25 carbon atom(s). ### Claim 2 (depends on 1) The method for treating skin cancer according to claim 1, further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof. ### Claim 3 (depends on 1) The method for treating skin cancer according to claim 1, wherein the skin cancer is selected from one of the groups comprising basal cell carcinoma, squamous cell carcinoma, melanoma, and merkel cell carcinoma. ### Claim 4 A method for treating skin cancer, comprising the step(s) of: administering a surfactant or a pharmaceutically acceptable salt thereof to a patient having skin cancer, wherein the protonated form of the surfactant is represented by the following chemical structure: wherein X comprises an integer ranging from approximately 2 to approximately 16, and wherein Y comprises an integer ranging from approximately 6 to approximately 16. ### Claim 5 (depends on 4) The method for treating skin cancer according to claim 4, further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof. ### Claim 6 (depends on 4) The method for treating skin cancer according to claim 4, wherein the skin cancer is selected from one of the groups comprising basal cell carcinoma, squamous cell carcinoma, melanoma, and merkel cell carcinoma. ### Claim 7 A method for treating skin cancer, comprising the step(s) of: administering a surfactant or a pharmaceutically acceptable salt thereof to a patient having skin cancer, wherein the surfactant is represented by the following chemical structure: wherein R1 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and/or cyano group containing 1 to approximately 25 carbon atom(s); wherein R2 is NCS; and wherein R3-R5 are each independently selected from the group consisting of H, OH, and an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and/or cyano group containing 1 to approximately 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and/or cyano group containing approximately 8 to approximately 25 carbon atom(s), and wherein X is a counter cation. ### Claim 8 (depends on 7) The method for treating skin cancer according to claim 7, further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof. ### Claim 9 (depends on 7) The method for treating skin cancer according to claim 7, wherein the skin cancer is selected from one of the groups comprising basal cell carcinoma, squamous cell carcinoma, melanoma, and merkel cell carcinoma.